Breaking News, Collaborations & Alliances

Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals

Supporting R&D optimization of next-generation biopharmaceuticals with digital technology and drug discovery platform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hitachi and Axcelead have entered a partnership to develop solutions contributing to more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery. Hitachi has also made an investment into Drug Discovery Gateway Fund (DDG Fund) managed by Whiz Partners. Axcelead is the flagship portfolio company of DDG Fund.   Through this collaboration, Hitachi and Axcelead will develop solutions that support the more efficient creation of next-generation biopharmaceut...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters